Sakar Healthcare Q3 FY26: Revenue up 62% YoY, PAT more than doubles

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

SAKAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+6.0%Reaction day

₹410.00

prior close

₹427.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.0%+7.0% vs market

Pharmaceuticals peers, median of 157sector-0.5%+6.5% vs sector

On the reaction day the stock moved 7.0 pts more than Nifty Microcap 250 and 6.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+1.9

15m

+2.1

30m

+1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+6.0-1.0+7.0-0.5+6.5

Next day

+7.3-1.8+9.1-1.2+8.5

+19.0+0.8+18.3+0.5+18.5

+12.2+1.8+10.4+1.0+11.2

+13.0+1.2+11.7+0.9+12.1

+14.6+0.7+13.9+0.0+14.6

+12.2-1.5+13.7-1.5+13.7

15d

+25.6-2.5+28.1-2.9+28.5

+28.4-7.2+35.6-5.1+33.5

+26.8-8.9+35.7-7.4+34.2

+53.4+5.5+48.0+0.2+53.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sakar Healthcare reported Q3 FY26 results (quarter ended 31 Dec 2025) on a standalone and consolidated basis. Revenue from operations rose 62% YoY to Rs 7,034.24 lakh (vs Rs 4,341.71 lakh). Nine-month revenue grew 42% to Rs 18,063.90 lakh. PAT surged 126% YoY to Rs 1,024.91 lakh; 9M PAT was Rs 1,946.02 lakh (up 66%). Q3 EPS stood at Rs 4.59 vs Rs 2.08. Statutory auditor J S Shah & Co issued an unqualified limited review report. Board meeting held on 5 February 2026.

Likely market impact

Strong Q3 with revenue up 62% and PAT more than doubling YoY; positive earnings momentum for shareholders.